We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
Read MoreHide Full Article
Shares of Humanigen, Inc. were down 76.6% on Wednesday after the company’s investigational COVID-19 treatment, lenzilumab failed in a late-stage study.
The National Institute of Allergy and Infectious Diseases’ (NIAID) ACTIV-5/BET-B study evaluated Humanigen’s lenzilumab plus Gilead’s (GILD - Free Report) Veklury (remdesivir) as compared to placebo plus remdesivir in treating hospitalized COVID-19 patients.
The study failed to achieve statistical significance on the primary endpoint —– defined as the proportion of patients with baseline CRP<150 mg/L and aged less than 85 years, alive and without mechanical ventilation through day 29.
The preliminary data from the ACTIV-5/BET-B study did not demonstrate a significant trend toward lowering mortality rates in the given patient population.
No new safety signals were observed for lenzilumab in the study. The benefit demonstrated in the ACTIV-5/BET-B study was not the same as that observed in previous studies on the candidate, like the phase III LIVE-AIR study
In March 2021, the company announced positive top-line data from the phase III LIVE-AIR study that evaluated lenzilumab in newly hospitalized COVID-19 patients.
The late-stage study showed encouraging data in survival without ventilation when treated with lenzilumab in combination with corticosteroids and remdesivir.
Humanigen’s stock has plunged 83.6% year to date compared with the industry’s decrease of 20.6%.
Image Source: Zacks Investment Research
Apart from COVID-19, Humanigen is also developing lenzilumab for treating other inflammatory indications like acute Graft versus Host Disease, eosinophilic asthma and rheumatoid arthritis.
In 2020, Gilead’s COVID treatment, Veklury, received FDA authorization for emergency use in adults and pediatric patients with severe-to-moderate COVID-19. The drug has received several label expansion approvals from the FDA for treating COVID-19 —– addressing various types of patient populations and different age groups.
For full-year 2022, GILD expects Veklury sales at around $2 billion.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 6.9% for 2022 and 2% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Precision BioSciences’ loss per share estimates narrowed 5.7% for 2022 and 16.2% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
Shares of Humanigen, Inc. were down 76.6% on Wednesday after the company’s investigational COVID-19 treatment, lenzilumab failed in a late-stage study.
The National Institute of Allergy and Infectious Diseases’ (NIAID) ACTIV-5/BET-B study evaluated Humanigen’s lenzilumab plus Gilead’s (GILD - Free Report) Veklury (remdesivir) as compared to placebo plus remdesivir in treating hospitalized COVID-19 patients.
The study failed to achieve statistical significance on the primary endpoint —– defined as the proportion of patients with baseline CRP<150 mg/L and aged less than 85 years, alive and without mechanical ventilation through day 29.
The preliminary data from the ACTIV-5/BET-B study did not demonstrate a significant trend toward lowering mortality rates in the given patient population.
No new safety signals were observed for lenzilumab in the study. The benefit demonstrated in the ACTIV-5/BET-B study was not the same as that observed in previous studies on the candidate, like the phase III LIVE-AIR study
In March 2021, the company announced positive top-line data from the phase III LIVE-AIR study that evaluated lenzilumab in newly hospitalized COVID-19 patients.
The late-stage study showed encouraging data in survival without ventilation when treated with lenzilumab in combination with corticosteroids and remdesivir.
Humanigen’s stock has plunged 83.6% year to date compared with the industry’s decrease of 20.6%.
Image Source: Zacks Investment Research
Apart from COVID-19, Humanigen is also developing lenzilumab for treating other inflammatory indications like acute Graft versus Host Disease, eosinophilic asthma and rheumatoid arthritis.
In 2020, Gilead’s COVID treatment, Veklury, received FDA authorization for emergency use in adults and pediatric patients with severe-to-moderate COVID-19. The drug has received several label expansion approvals from the FDA for treating COVID-19 —– addressing various types of patient populations and different age groups.
For full-year 2022, GILD expects Veklury sales at around $2 billion.
Zacks Rank & Stocks to Consider
Humanigen currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Leap Therapeutics, Inc. (LPTX - Free Report) and Precision BioSciences, Inc. (DTIL - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 6.9% for 2022 and 2% for 2023 in the past 60 days.
Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.
Precision BioSciences’ loss per share estimates narrowed 5.7% for 2022 and 16.2% for 2023 in the past 60 days.
Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.